Diabetic Retinopathy (DR)

exp date isn't null, but text field is

CLINICAL DESCRIPTIONMicrovascular damage to the retina secondary to diabetic hyperglycemia.

There are two main classes of the disease;

  • Non-Proliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy

 

NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR)

CLINICAL DESCRIPTION

This is the early stage of DR characterized by the presence of haemorrhages and microaneurysms on the retina. The retinal blood vessels may leak resulting in intra-retinal fluid accumulation and leakage of exudates. When this happens in the macula, it is called macular oedema, and this is the most common reason why people with diabetes lose their vision. Retinal microvascular obstruction in the macula may also occur resulting in macular ischemia.  

PROLIFERATIVE DIABETIC RETINOPATHY (PDR)

CLINICAL DESCRIPTION

PDR is the more advanced stage of diabetic retinopathy characterized by retinal neovascularization i.e., growth of fragile new blood vessels on the retina. The new vessels often bleed into the vitreous and can form fibrous tissue that results in a tractional pull on the retina.

CLINICAL FEATURES

SIGNS AND SYMPTOMS

Symptoms of diabetic retinopathy:

  • Changes in vision
    • Blurry vision or intermittent changes from blurry to clear   
    • Blank or dark areas in the field of vision
    • Poor night vision, and
    • Faded or washed-out colors  
    • Visual loss.
  • Floaters

TREATMENT

Management of PDR

  • Pan retinal photocoagulation with argon laser
  • consider Intravitreal Anti Vascular endothelial growth factors (Anti VEGFs) eg Bevacizumab, Ranibizumab, Aflibercept
  • Vitrectomy for PDR with tractional retinal detachment

Management of Clinically Significant Macular Oedema

  • Focal/grid macular laser
  • Intravitreal Anti VEGFs (eg Bevacizumab, Ranibizumab, Aflibercept) once monthly for 4 months or more depending on response

REFERRAL CRITERIA

  • Refer to a tertiary facility when fundoscopy shows any of the following:
    • Severe NPDR
      • Presence of hemorrhages in four quadrants of the retina or if there is venous beading in two quadrants or if there are intraretinal microvascular abnormalities in one quadrant of the retina.
    • PDR
      • Presence of features such as new vessels or fibrosis on the retina, vitreous hemorrhage, preretinal hemorrhage or tractional retinal detachment
    • Clinically significant macular oedema (CSMO)
      • Retinal thickening at or within 500 μm of the center of the macula. 
      • Hard exudates at or within 500 μm of the center of the macula, if associated with adjacent retinal thickening; or a zone or zones of retinal thickening one disc area in size, at least part of which is within one disc diameter of the center of the macula